We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04270682
Recruitment Status : Recruiting
First Posted : February 17, 2020
Last Update Posted : March 2, 2023
Sponsor:
Information provided by (Responsible Party):
Travere Therapeutics, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study is made up of two cohorts: a randomized double-blind crossover (placebo withdrawal with rescue) study among patients ≥ 16 years of age (adult cohort) and an open-label dose titration study among pediatric patients ≥1 month and <16 years of age (pediatric cohort)

Condition or disease Intervention/treatment Phase
CTX Drug: Blinded CDCA 250 mg TID Drug: Placebo Drug: Open-Label CDCA 250 mg TID Drug: Rescue Medication CDCA 250 mg TID Drug: CDCA Weight-Based Dose TID Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Two-cohort study. One cohort is for adult patients with a double-blind placebo withdrawal (with CDCA rescue) crossover. Second cohort will dose titrate pediatric patients into a stable, open-label treatment.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis
Actual Study Start Date : January 31, 2020
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Adult Cohort
Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
 Drug: Blinded CDCA 250 mg TID
Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.

Drug: Placebo
Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.

Drug: Open-Label CDCA 250 mg TID
Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.

Drug: Rescue Medication CDCA 250 mg TID
CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
Experimental: Pediatric Cohort
Pediatric cohort patients (≥1 month and <16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
 Drug: CDCA Weight-Based Dose TID
Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Bile Alcohols. [ Time Frame: Week 4 and Week 16 ]
    Change from baseline in bile alcohols at the end of each DB treatment period.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female at least 1 month or older at screening.
  2. Clinical diagnosis of CTX with biochemical confirmation.
  3. Women of childbearing potential must agree to the use of one highly reliable method of contraception during the study, plus one additional barrier method during sexual activity.
  4. Males must be surgically sterile, or males and their sexual partners must together agree to use medically accepted methods of contraception that are considered highly reliable during the course of the study.

Exclusion Criteria:

  1. Genetic testing does not confirm CTX.
  2. Malabsorption disorder or confounding inflammatory gastrointestinal condition (for example, irritable bowel syndrome).
  3. Documented history of heart failure.
  4. Treated with medications which impact bile acid absorption such as bile acid sequestering agents (eg, cholestyramine, colestipol, aluminum-based antacids.
  5. Treated with cholic acid medication.
  6. Female patient who is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.
  7. Positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B infection or hepatitis C infection.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04270682


Contacts
Layout table for location contacts
Contact: Travere Medical Information 1-877-659-5518 medinfo@travere.com

Locations
Layout table for location information
United States, Colorado
Travere Investigational Site Active, not recruiting
Aurora, Colorado, United States, 80045
United States, Florida
Travere Investigational Site Active, not recruiting
Orlando, Florida, United States, 32806
United States, Iowa
Travere Investigational Site Completed
Iowa City, Iowa, United States, 52242
United States, Louisiana
Travere Investigational Site Completed
New Orleans, Louisiana, United States, 70112
Travere Investigational Site Completed
New Orleans, Louisiana, United States, 70121
United States, New York
Travere Investigational Site Completed
Great Neck, New York, United States, 11021
United States, Ohio
Travere Investigational Site Completed
Columbus, Ohio, United States, 43221
United States, Texas
Travere Investigational Site Completed
Austin, Texas, United States, 78723
United States, Washington
Travere Investigational Site Completed
Seattle, Washington, United States, 98195
Brazil
Travere Investigational Site Recruiting
Fortaleza, CE, Brazil, 60430-270
Principal Investigator: Cheno-CTX-301 Investigator         
Travere Investigational Site Recruiting
Porto Alegre, RS, Brazil, 90035-903
Principal Investigator: Cheno-CTX-301 Investigator         
Travere Investigational Site Recruiting
São Paulo, SP, Brazil, 04024-002
Contact: Cheno-CTX-301 Investigator         
Sponsors and Collaborators
Travere Therapeutics, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Travere Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04270682    
Other Study ID Numbers: Cheno-CTX-301
First Posted: February 17, 2020    Key Record Dates
Last Update Posted: March 2, 2023
Last Verified: March 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Travere Therapeutics, Inc.:
Cerebrotendinous xanthomatosis
CTX
Cholestanol
Leukodystrophy
CYP27A1
Additional relevant MeSH terms:
Layout table for MeSH terms
Xanthomatosis, Cerebrotendinous
Xanthomatosis
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
 Metabolism, Inborn Errors
Genetic Diseases, Inborn
Chenodeoxycholic Acid
Cathartics
Gastrointestinal Agents